{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:26:30Z","timestamp":1788200790352,"version":"build-2803163510"},"update-to":[{"DOI":"10.1371\/journal.pmed.1004505","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000}}],"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["21 1690 Pj"],"award-info":[{"award-number":["21 1690 Pj"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007232","name":"Radiumhemmets Forskningsfonder","doi-asserted-by":"publisher","award":["234172"],"award-info":[{"award-number":["234172"]}],"id":[{"id":"10.13039\/501100007232","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002860","name":"China Sponsorship Council","doi-asserted-by":"publisher","award":["202206160010"],"award-info":[{"award-number":["202206160010"]}],"id":[{"id":"10.13039\/501100002860","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Evidence on invasive cervical cancer prevention among older women is limited, especially with the introduction of human papillomavirus (HPV)-based screening and longer interval. We conducted a long-term follow-up of the first phase of a randomized healthcare policy trial in cervical screening, targeting women aged 56 to 61 years old, to investigate the effectiveness of primary HPV-based screening in preventing invasive cervical cancer (ICC) and the safety of extending screening interval.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods and findings<\/jats:title>\n<jats:p>The randomized healthcare policy trial of primary HPV-based cervical screening targeted women residing in Stockholm-Gotland region during 2012 to 2016, aged 30 to 64 years. The trial aimed to investigate the detection rate of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) within 24 months and long-term protection against invasive cervical cancer, comparing primary HPV-based screening to primary cytology-based screening. The initial phase of the trial, which was the focus of this study, targeted women aged 56 to 61 years old in 2012 to 2014 who were randomized to primary cytology arm (<jats:italic>n<\/jats:italic> = 7,401) or primary HPV arm (<jats:italic>n<\/jats:italic> = 7,318). We used national registries to identify the subsequent cervical tests and all histopathological diagnoses including ICC before December 31, 2022. We calculated cumulative incidence, incidence rate (IR) and IR ratio (IRR) of ICC, by baseline test result. Furthermore, we calculated longitudinal sensitivity and specificity for detecting cervical intraepithelial neoplasia grade 2 or worse (CIN2+) by receipt of primary cytology or primary HPV test for the recommended screening intervals in this age group.<\/jats:p>\n<jats:p>We found that the IR of ICC among women in the primary HPV arm was 7.2\/100,000 person-years (py) and 3.0 for women who tested HPV negative, compared to 18.4\/100,000 py among women in the primary cytology arm and 18.8 for women who tested cytology negative. We further found that the overall point estimate for the risk of ICC over 10 years of follow-up among women in the primary HPV arm was 0.39 compared to women in the primary cytology arm, but this was not statistically significant (IRR: 0.39; 95% confidence interval, CI [0.14, 1.09]; <jats:italic>p<\/jats:italic> = 0.0726). However, among women with a negative test result at baseline, women in the primary HPV arm had an 84% lower risk of ICC compared to women in the primary cytology arm (IRR: 0.16; 95% CI [0.04, 0.72]; <jats:italic>p<\/jats:italic> = 0.0163). Moreover, primary HPV testing had a higher sensitivity for detecting CIN2+ within a 7-year interval than primary cytology testing within a 5-year interval (89.6% versus 50.9%, <jats:italic>p<\/jats:italic> &lt; 0.0001). We were limited by a partial imbalance of invitations during the follow-up between the 2 arms which may have led to an underestimation of the effectiveness of primary HPV-based screening.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>In this study, we observed that women over 55 years of age who received a primary negative HPV test result had substantially lower risk of CIN2+, and ICC, compared to women who received a primary negative cytology result. This should apply even if the screening interval were prolonged to 7 years.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Trial Registration<\/jats:title>\n<jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01511328\" xlink:type=\"simple\">NCT01511328<\/jats:ext-link>.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pmed.1004505","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T18:54:42Z","timestamp":1734634482000},"page":"e1004505","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Evaluation of primary HPV-based cervical screening among older women: Long-term follow-up of a randomized healthcare policy trial in Sweden"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2737-7070","authenticated-orcid":true,"given":"Qingyun","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0001-503X","authenticated-orcid":true,"given":"Jiangrong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0514-7226","authenticated-orcid":true,"given":"K. Miriam","family":"Elfstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8369-7955","authenticated-orcid":true,"given":"Bj\u00f6rn","family":"Strander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8588-6506","authenticated-orcid":true,"given":"Joakim","family":"Dillner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6865-0224","authenticated-orcid":true,"given":"Karin","family":"Sundstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"key":"pmed.1004505.ref001","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejca.2016.12.021","article-title":"Cervical cancer incidence in elderly women-biology or screening history?","volume":"74","author":"E Lynge","year":"2017","journal-title":"Eur J Cancer"},{"key":"pmed.1004505.ref002","article-title":"Socialstyrelsen Cancer Statistics Database [Internet].","author":"Socialstyrelsen","year":"2024"},{"key":"pmed.1004505.ref003","unstructured":"Global strategy to accelerate the elimination of cervical cancer as a public health problem [Internet]. Available from: https:\/\/www.who.int\/publications-detail-redirect\/9789240014107 [accessed: 12\/08\/2024]."},{"issue":"8","key":"pmed.1004505.ref004","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/aogs.14162","article-title":"Cervical cancer prevention among older women\u2014challenges in screening, diagnostic workup and treatment.","volume":"100","author":"LW Gustafson","year":"2021","journal-title":"Acta Obstet Gynecol Scand."},{"issue":"6","key":"pmed.1004505.ref005","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/ijc.2910630610","article-title":"Low efficiency of cytologic screening for cancer in situ of the cervix in older women","volume":"63","author":"L Gustafsson","year":"1995","journal-title":"Int J Cancer"},{"issue":"8","key":"pmed.1004505.ref006","doi-asserted-by":"crossref","first-page":"e1115","DOI":"10.1016\/S2214-109X(22)00241-8","article-title":"Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis.","volume":"10","author":"L Bruni","year":"2022","journal-title":"Lancet Glob Health."},{"issue":"5","key":"pmed.1004505.ref007","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.cmi.2019.09.006","article-title":"Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans","volume":"26","author":"PJ Maver","year":"2020","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"pmed.1004505.ref008","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3322\/caac.21628","article-title":"Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society.","volume":"70","author":"ETH Fontham","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"pmed.1004505.ref009","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pvr.2015.06.006","article-title":"European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination","volume":"1","author":"LV Karsa","year":"2015","journal-title":"Papillomavirus Res"},{"key":"pmed.1004505.ref010","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ypmed.2018.07.005","article-title":"How confident can we be in the current guidelines for exiting cervical screening?","volume":"114","author":"PE Gravitt","year":"2018","journal-title":"Prev Med."},{"key":"pmed.1004505.ref011","doi-asserted-by":"crossref","first-page":"i4924","DOI":"10.1136\/bmj.i4924","article-title":"Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands","volume":"355","author":"MG Dijkstra","year":"2016","journal-title":"BMJ"},{"issue":"6","key":"pmed.1004505.ref012","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1002\/ijc.32950","article-title":"A study of the risks of CIN3+ detection after multiple rounds of HPV testing: Results of the 15-year cervical cancer screening experience at Kaiser Permanente Northern California","volume":"147","author":"A Hammer","year":"2020","journal-title":"Int J Cancer"},{"key":"pmed.1004505.ref013","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ygyno.2023.11.036","article-title":"Similar effectiveness with primary HPV and cytology screening\u2014Long-term follow-up of randomized cervical cancer screening trial","volume":"180","author":"M Vahteristo","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"5","key":"pmed.1004505.ref014","doi-asserted-by":"crossref","first-page":"e014788","DOI":"10.1136\/bmjopen-2016-014788","article-title":"Randomised healthcare policy evaluation of organised primary human papillomavirus screening of women aged 56\u201360","volume":"7","author":"H Lamin","year":"2017","journal-title":"BMJ Open"},{"issue":"12","key":"pmed.1004505.ref015","doi-asserted-by":"crossref","first-page":"e0209003","DOI":"10.1371\/journal.pone.0209003","article-title":"Cervical cancer screening in Sweden 2014\u20132016.","volume":"13","author":"M Hortlund","year":"2018","journal-title":"PLoS ONE."},{"issue":"6","key":"pmed.1004505.ref016","doi-asserted-by":"crossref","first-page":"e0217108","DOI":"10.1371\/journal.pone.0217108","article-title":"HPV-based screening for cervical cancer among women 55\u201359 years of age.","volume":"14","author":"L Bergengren","year":"2019","journal-title":"PLoS ONE."},{"issue":"3","key":"pmed.1004505.ref017","first-page":"389","article-title":"Human Papillomavirus Testing in the Last Cervical Screening Round at Age 60\u201364 Years.","volume":"138","author":"JB Schroll","year":"2021","journal-title":"Obstet Gynecol.1"},{"issue":"12","key":"pmed.1004505.ref018","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1002\/ijc.27561","article-title":"Randomised health services studies","volume":"131","author":"M Hakama","year":"2012","journal-title":"Int J Cancer"},{"issue":"3","key":"pmed.1004505.ref019","doi-asserted-by":"crossref","first-page":"253.e1","DOI":"10.1016\/j.ajog.2019.09.039","article-title":"Colposcopic and histopathologic evaluation of women with HPV persistence exiting an organized screening program.","volume":"222","author":"H Sahlgren","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"pmed.1004505.ref020","unstructured":"Swedish National Cervical Screening Registry [Internet]. Available from: https:\/\/nkcx.se\/index_e.htm [accessed: 12\/08\/2024]."},{"issue":"3","key":"pmed.1004505.ref021","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1080\/0284186X.2017.1366048","article-title":"Data quality in the Swedish Quality Register of Gynecologic Cancer\u2013a Swedish Gynecologic Cancer Group (SweGCG) study.","volume":"57","author":"P Rosenberg","year":"2018","journal-title":"Acta Oncol"},{"issue":"3","key":"pmed.1004505.ref022","first-page":"125","article-title":"Histopathology of cervical precursor lesions and cancer","volume":"20","author":"S. Lax","year":"2011","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"issue":"11\u201312","key":"pmed.1004505.ref023","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/sim.4443","article-title":"Performance of binary markers for censored failure time outcome: nonparametric approach based on proportions.","volume":"31","author":"L Antolini","year":"2012","journal-title":"Stat Med."},{"issue":"6","key":"pmed.1004505.ref024","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.jclinepi.2012.09.018","article-title":"A framework provided an outline toward the proper evaluation of potential screening strategies.","volume":"66","author":"WJ Adriaensen","year":"2013","journal-title":"J Clin Epidemiol."},{"issue":"11","key":"pmed.1004505.ref025","doi-asserted-by":"crossref","first-page":"e886","DOI":"10.1016\/S2468-2667(24)00218-4","article-title":"Human papillomavirus-based cervical screening and long-term cervical cancer risk: a randomised health-care policy trial in Sweden.","volume":"9","author":"J Wang","year":"2024","journal-title":"Lancet Public Health"},{"issue":"8","key":"pmed.1004505.ref026","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.cmi.2021.04.031","article-title":"2020 list of human papillomavirus assays suitable for primary cervical cancer screening","volume":"27","author":"M Arbyn","year":"2021","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"pmed.1004505.ref027","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1177\/0969141321992820","article-title":"Hybrid capture 2 and cobas 4800: Comparison of performance of two clinically validated tests for human papillomavirus primary screening of cervical cancer","volume":"28","author":"A Mongia","year":"2021","journal-title":"J Med Screen"},{"key":"pmed.1004505.ref028","doi-asserted-by":"crossref","first-page":"105581","DOI":"10.1016\/j.jcv.2023.105581","article-title":"First international proficiency study on human papillomavirus testing in cervical cancer screening","volume":"167","author":"E Yilmaz","year":"2023","journal-title":"J Clin Virol"},{"issue":"14","key":"pmed.1004505.ref029","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/jnci\/dji187","article-title":"The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.","volume":"97","author":"MJ Khan","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"pmed.1004505.ref030","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/LGT.0000000000000525","article-title":"2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors.","volume":"24","author":"RB Perkins","year":"2020","journal-title":"J Low Genit Tract Dis"},{"key":"pmed.1004505.ref031","doi-asserted-by":"crossref","first-page":"g130","DOI":"10.1136\/bmj.g130","article-title":"Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial","volume":"348","author":"KM Elfstr\u00f6m","year":"2014","journal-title":"BMJ"},{"issue":"10","key":"pmed.1004505.ref032","doi-asserted-by":"crossref","first-page":"e1004115","DOI":"10.1371\/journal.pmed.1004115","article-title":"Risk of cervical precancer among HPV-negative women in the Netherlands and its association with previous HPV and cytology results: A follow-up analysis of a randomized screening study.","volume":"19","author":"F Inturrisi","year":"2022","journal-title":"PLoS Med."}],"updated-by":[{"DOI":"10.1371\/journal.pmed.1004505","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000}}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004505","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T18:49:48Z","timestamp":1736275788000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004505"}},"subtitle":[],"editor":[{"given":"Elvin Hsing","family":"Geng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":32,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004505","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pmed.1004505","asserted-by":"object"}]},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,19]]}}}